Will SoundHound AI Stock Recover?
SoundHound AI (NASDAQ:SOUN) is a leading maker of artificial intelligence…
Sell
17
TRAW Quote, Financials, Valuation and Earnings
Last price:
$2.43
Seasonality move
:
-9.22%
Day range:
$2.36 - $2.67
52-week range:
$2.02 - $27.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
9.71x
P/B ratio:
2.78x
Volume:
26.6K
Avg. volume:
103.4K
1-year change:
-90.5%
Market cap:
$7.3M
Revenue:
$226K
EPS (TTM):
-$141.47
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Traws Pharma has 150% upside to fair value with a price target of -- per share.
TRAW vs. S&P 500
-
Over the past 5 trading days, Traws Pharma has underperformed the S&P 500 by -14.18% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Traws Pharma does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Traws Pharma has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Traws Pharma reported revenues of $57K.
Earnings Growth
-
Traws Pharma has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Traws Pharma reported earnings per share of -$8.81.
Enterprise value:
1.9M
EV / Invested capital:
--
Price / LTM sales:
9.71x
EV / EBIT:
--
EV / Revenue:
8.19x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-0.06x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-736.98%
Net Income Margin (TTM):
-62294.25%
Return On Equity:
-124.39%
Return On Invested Capital:
-124.39%
Operating Margin:
-14975.44%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $226K | $226K | $226K | $57K | $57K | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$17.7M | -$21.6M | -$24.1M | -$5.1M | -$8.5M | |
| EBITDA | -$17.6M | -$21.6M | -$24.1M | -$5.1M | -$8.5M | |
| Diluted EPS | -$20.25 | -$24.14 | -$141.47 | -$5.64 | -$8.81 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $25M | $59.9M | $43.8M | $27M | $8.9M | |
| Total Assets | $25.2M | $60M | $43.8M | $27M | $8.9M | |
| Current Liabilities | $9.3M | $7M | $7.3M | $9.7M | $8.3M | |
| Total Liabilities | $13M | $10.3M | $10.4M | $12.5M | $11M | |
| Total Equity | $12.2M | $49.7M | $33.4M | $14.5M | -$2M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$16.7M | -$17.4M | -$30.2M | -$4.5M | -$11.5M | |
| Cash From Investing | -- | -- | -- | -$14K | -- | |
| Cash From Financing | -- | -- | -- | -- | -- | |
| Free Cash Flow | -$16.7M | -$17.4M | -$30.2M | -$4.5M | -$11.5M | |
TRAW
Sector
Market Cap
$7.3M
$36.5M
Price % of 52-Week High
8.73%
44.66%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.9%
1-Year Price Total Return
-90.5%
-39.9%
Beta (5-Year)
1.422
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$2.69
200-day SMA
Sell
Level
$7.20
Bollinger Bands (100)
Sell
Level
3.26 - 7.8
Chaikin Money Flow
Sell
Level
-462.2M
20-day SMA
Sell
Level
$2.71
Relative Strength Index (RSI14)
Sell
Level
28.95
ADX Line
Sell
Level
27.06
Williams %R
Buy
Level
-95.4576
50-day SMA
Sell
Level
$4.88
MACD (12, 26)
Sell
Level
-0.64
25-day Aroon Oscillator
Sell
Level
-24
On Balance Volume
Neutral
Level
2.2B
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-31.2379)
Sell
CA Score
(Annual)
Level (-2.8237)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (5.9078)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Traws Pharma Inc is a biopharmaceutical company focused on developing antivirals for influenza, COVID and other respiratory infections and narazaciclib.
Stock Forecast FAQ
In the current month, TRAW has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The TRAW average analyst price target in the past 3 months is --.
-
Where Will Traws Pharma Stock Be In 1 Year?
According to analysts, the consensus estimate is that Traws Pharma share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Traws Pharma?
Analysts are divided on their view about Traws Pharma share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Traws Pharma is a Sell and believe this share price will drop from its current level to --.
-
What Is Traws Pharma's Price Target?
The price target for Traws Pharma over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is TRAW A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Traws Pharma is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of TRAW?
You can purchase shares of Traws Pharma via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Traws Pharma shares.
-
What Is The Traws Pharma Share Price Today?
Traws Pharma was last trading at $2.43 per share. This represents the most recent stock quote for Traws Pharma. Yesterday, Traws Pharma closed at $2.40 per share.
-
How To Buy Traws Pharma Stock Online?
In order to purchase Traws Pharma stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Stocks Did Warren Buffett Just Buy?
In Q4 of last year, Warren Buffett added to or…
Is it Finally Time to Buy Medical Properties Trust?
Medical Properties Trust (NYSE:MPW) is a REIT that focuses on…
Stock Ideas
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
41
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
78
AJINY alert for Mar 29
Ajinomoto [AJINY] is up 99.61% over the past day.
Buy
69
AGX alert for Mar 29
Argan [AGX] is up 19.83% over the past day.
Sell
24
AIR alert for Mar 29
AAR [AIR] is down 16.36% over the past day.
